Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia

Blood

Volumn 94, Issue 4, 1999, Pages 1209-1217

  Dördelmann, Michael ^a   Reiter, Alfred ^b   Borkhardt, Arndt ^b   Ludwig, Wolf Dieter ^b   Götz, Nicolai ^b   Viehmann, Susanne ^b   Gadner, Helmut ^b   Riehm, Hansjörg ^b   Schrappe, Martin ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CHROMOSOME REARRANGEMENT; DRUG RESPONSE; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

EID: 0344246893     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.4.1209.416k05_1209_1217     Document Type: Article

References (68)

1. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605, 1998
2. Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F: Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group Study. Blood 67:135, 1986
3. Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R, Miller DR, Sather HN, Hammond GD: Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 71:1033, 1987
4. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM: Acute lymphoblastic leukaemia in infancy: Experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 8:1275, 1994
5. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC, Head DR, Mahmoud HH, Sandlund JT, Furman WL: 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12:909, 1994
6. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G, Thyss A, Robert A, Mazingue F, Souillet G: Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 86:284, 1994
7. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ, Steinherz PG, Zeltzer P, Hammond D, Reaman GH: Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: A report of the Childrens Cancer Group. Blood 83:2274, 1994
8. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
9. Silverman LB, Mclean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, Sallan SE: Intensified therapy for infants with acute lymphoblastic leukemia. Cancer 80:2285, 1997
10. Lauer SJ, Camitta BM, Leventhal BG, Mahoney D, Shuster JJ, Kiefer G, Pullen DJ, Steuber CP, Carroll AJ, Kamen B: Intensive alternating drug pairs after remission induction fot treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 20:229, 1998
11. Mulhern RK, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, Kun LE: Long-term survivors of leukemia treated in infancy: Factors associated with neuropsychologic status. J Clin Oncol 10:1095, 1992
12. Kaleita TA, MacLean WE, Reaman GH: Neurodevelopmental outcome of childen diagnosed with ALL during infancy: A preliminary report from the Childrens Cancer Group. Med Pediatr Oncol 5:385, 1992
13. Cimino G, Rapanotti MC, Rivolta A, Lo Coco F, D'Arcangelo E, Rondelli R, Basso G, Barisone E, Rosanda C, Santostasi T: Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 9:391, 1995
14. Hilden JM, Frestedt JL, Moore RO, Heerema NA, Arthur DC, Reaman GH, Kersey JH: Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 86:3876, 1995
15. Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K, Sako M, Tsuchida M, Seto M, Ueda R, Hayashi Y: Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 10:1303, 1996
16. Pui CH, Ribeiro RC, Campana D, Raimondi SC, Hancock ML, Behm FG, Sandlund JT, Rivera GK, Evans WE, Crist WM, Krance R: Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 10:952, 1996
17. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87:2870, 1996
18. Dinndorf PA, Reaman GH: Acute lymphoblastic leukemia in infants: Evidence of B-cell orign of disease by use of monoclonal antibody phenotyping. Blood 68:9756, 1986
19. Pui CH, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases. Blood 77:440, 1991
20. Chen CS, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA, Hammond GD, Kersey JH: Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81:2386, 1993
21. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML: Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 84:570, 1994
22. Riehm H, Reiter A, Schrappe M: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151, 1987
23. Schrappe M, Reiter A, Sauter S, Ludwig WD, Wormann B, Harbott J, Bender-Gotze C, Dorffel W, Dopfer R, Frey E, Riehm H: Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow. Klin Padiatr 206:208, 1994
24. Schrappe M, Reiter, Riehm H: Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2403, 1996
25. +) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730, 1998
26. Sackmann Muriel F, Felice MS, Zubizarreta P, Chantada G, Barbieri MF, Rossi J: Improved outcome in higher-risk acute lymphoblastic leukemia with a hybrid (Berlin-Frankfurt-Münster/St. Jude's) therapy. Int J Pediatr Hematol Oncol 3:439, 1996
27. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G: Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 75:1684, 1995
28. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, Löffler H, Hossfeld D, Heil Gerhard, Handt S, Heyll A, Diedrich H, Fischer K, Weiss A, Völkers B, Aydemir Ü, Fonatsch C, Gökbuget N, Thiel E, Hoelzer D: Immunophenotyping and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trial GMALL 03/87 and 04/89. Blood 92:1898, 1998
29. Harbott J, Ritterbach J, Ludwig WD: Clinical significance of cytogenetic studies in childhood acute leukemia: Experience of the BFM trials. Rec Res Cancer Res 131:123, 1993
30. Hiddemann W, Wörmann B, Ritter J: Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann NY Acad Sci 468:227, 1986
31. Janssen JWG, Ludwig WD, Borkhardt A, Spadinger U, Rieder H, Fonatsch C, Hossfeld DK, Harbott J, Schulz A, Repp R, Sykora KW, Hoelzer D, Bartram CR: Pre-pre B acute lymphoblastic leukemia: High frequency of alternatively ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 84:3835, 1994
32. Langermann HJ, Henze G, Wulf M: Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: Prognostische Bedeutung und praktische Anwendung. Klin Padiatr 194:209, 1982
33. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 52:457, 1958
34. Greenwood M: The natural duration of cancer, in Reports on Public Health and Medical Subjects, 33. London, UK, Her Majesty's Stationary Office, 1926, p 1
35. Cox DR: Regression modells and life tables. J R Stat Soc 34:187, 1972
36. Sather HN: Age at diagnosis in childhood acute lymphoblastic leukemia. Med Ped Oncol 14:166, 1986
37. Basso G, Putti MC, Cantu Rajnoldi A, Saitta M, Santostasi T, Santoro N, Lippi A, Comelli A, Felici L, Favre C: The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP). Br J Haematol 81:184, 1992
38. Pui CH, Crist WM, Look AT: Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449, 1990
39. Biondi A, Rossi V, di Celle PF, Carbone A, Benvestito S, Busca A, Giudici G, Giachino C, Basso G, Foa R: Unique genotypic features of infant acute lymphoblastic leukaemia at presentation and at relapse. Br J Haematol 80:472, 1992
40. Pui CH, Carroll LAJ, Raimondi SC, Shuster JJ, Crist WM, Pullen DJ: Childhood acute lymphoblastic leukemia with the t(4;11)(q21; q23): An update (letter). Blood 83:2384, 1994
41. Downing JR, Head DR, Raimondi SC, Carroll AJ, Curcio Brint AM, Motroni TA, Hulshof MG, Pullen DJ, Domer PH: The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4; 11)(q21;q23)-containing acute lymphoblastic leukemia. Blood 83:330, 1994
42. Biondi A, Rambaldi A, Rossi V, Elia L, Caslini C, Basso G, Battista R, Barbui T, Mandelli F, Masera G: Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 82:2943, 1993
43. Gibbons B, Katz FE, Ganly P, Chessells JM: Infant acute lymphoblastic leukemia with t(11,19). Br J Haematol 74:264, 1990
44. Huret JL, Brizart A, Slater R, Charrin C, Bertheas MF, Guilhot F, Hählen K, Kroes W, van Leuwen E, Schoot EVD, Beishuizen A, Tanzer J, Tangemeijer A: Cytogenetic heterogenetity in t(11;19) acute leukemia: Clinical, hematological and cytogenetic analyses of 48 patients -Updated published cases and 16 new observations. Leukemia 7:152, 1993
45. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker Walker LM, on behalf of the European 11q23 Workshop participants: The translocations t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): A cytogenetic and clinical profile of 53 patients. Leukemia 12:805, 1998
46. Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L, Sarquis MB, Bostrom B, Nachman JB, Steinherz PG, Gaynon P, Heerema N: Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 92:810, 1998
47. Hunger SP, Cleary ML: What significance should we attribute to the detection of MLL fusion transcripts? Blood 92:709, 1998
48. Bernard OA, Berger R: Molecular basis of 11q23 rearrangements in hematopoetic malignant proliferations (review). Genes Chromosom Cancer 13:75, 1995
49. Greaves MF: Infant leukaemia biology, aetiology and treatment. Leukemia 10:372, 1996
50. Ito C, Evans WE, McNinch L, Coustan Smith E, Mahmoud H, Pui CH, Campana D: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370, 1996
51. Pinkel D: Selecting treatment for children with acute lymphoblastic leukemia. J Clin Oncol 14:4, 1996
52. Rautonen J, Hovi L, Siimes MA: Slow disappearance of peripheral blast cells: An independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 71:989, 1988
53. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, Crist WM, Pui CH: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292, 1995
54. Jacquillat C, Weil M, Gemon MF, Auclerc G, Loisel JP, Delobel J, Flandrin G, Schaison G, Izrael V, Bussel A, Dresch C, Weisgerber C, Rain D, Tanzer J, Najean Y, Seligmann M, Boiron M, Bernard J: Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). Cancer Res 33:3278, 1973
55. Frei E III, Sallan SE: Acute lymphoblastic leukemia: Treatment. Cancer 42:828, 1978
56. Miller DR, Coccia PF, Bleyer WA, Lukens JN, Siegel SE, Sather HN, Hammond D: Early response to induction therapy as a predictor of disease free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol 7:1807, 1989
57. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond D: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273, 1990
58. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chapell R, Hammond D, Bleyer WA: Cytoreduction and prognosis in acute lymphoblastic leukemia-The importance of early marrow response: Report from the Childrens Cancer Group. J Clin Oncol 14:389, 1996
59. Kumagai, Manabe A, Pui CH: Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 97:755, 1996
60. Kersey J, Wang D, Oberto M: Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to cell death induced by growth factor deprivation; a possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Blood 92:1987a, 1998 (abstr, suppl 1)
61. Uckun FM, Sather H, Reaman G: Leukemic cell growth in SCID mice as a predictor of relapse in high risk B-lineage acute lymphoblastic leukemia. Blood 85:873, 1995
62. Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Hählen K, van der Doos-van den Berg A, van Wering ER, Veerman AJP: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392, 1993
63. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP: Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19:407, 1995
64. Ramakers-van Woerden NL, Pieters R, Zwaan CM, Kaspers GJL, Beverloo HB, Loonen AH, Slater R, Harbott J, Schmiegelow K, Hählen K, van Wering ER, Ludwig WD, Haas O, Janka-Schaub G, Creutzig U, Veerman AJP: In vitro drug resistance profiles in infant acute leukemia: Implications for treatment? Blood 92:1592a, 1998 (abstr, suppl 1)
65. Gill Super HJ, Rothberg PG, Kobayashi H, Freeman AI, Diaz MO, Rowley JD: Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: In utero chromosome rearrangement of 11q23. Blood 83:641, 1994
66. Ridge SA, Cabrera ME, Ford AM, Tapia S, Risueno C, Labra S, Barriga F, Greaves MF: Rapid intraclonal switch of lineage dominance in congenital leukaemia with a MLL gene rearrangement. Leukemia 9:2023, 1995
67. Ludwig WD, Bartram CR, Harbott J, Koller U, Haas OA, Hansen Hagge T, Heil G, Seibt Jung H, Teichmann JV, Ritter J: Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia 3:431, 1989
68. Campbell M, Cabrera ME, Legues ME, Ridge S, Greaves M: Discordant clinical presentation and outcome in infant twins sharing a common clonal leukaemia. Br J Haematol 93:166, 1996